Novavax Inc (NVAX)
$103.45 3.59 (3.35%)
11:31 EDT NVAX Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 39.48B
PE Ratio -169.59
Volume (Avg. Vol.) 1.72M
Day's Range 100.37 - 108.20
52-Week Range 3.54 - 189.40
Dividend & Yield N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
- From InvestorPlace
- From the Web
By Thomas Niel
And, even with the NanoFlu catalyst serving as a backup, it may not be enough to shore up NVAX stock if its Covid-19 vaccine falls short of expectations. With all this uncertainty at play, tread carefully with NVAX stock.
The possibility of a combined vaccine for influenza and the coronavirus makes NVAX stock a very appealing growth opportunity.
A promising vaccine combination and longer-term price chart are just what the doctor ordered to turn around downtrodden NVAX stock.
There's a lot riding on Novavax's novel coronavirus vaccine candidate, making NVAX stock a biotech lottery ticket for bold traders.
Novavax has used its 15 minutes of fame to great success. But unless its Covid-19 vaccine launches soon, NVAX stock is set to decline.
Expect NVAX stock to exceed the $200 mark with two solid growth catalysts in its Covid 19 and Nanoflu vaccine
Novavax got a manufacturing partner in mid-September to make 2 billion doses. Despite NVAX stock going sideways since then, it remains a buy.
The coronavirus vaccine race is heating up and if you're looking for a potential winner, then now is the time to consider NVAX stock.
Louis Navellier zeroes in on eventual stock winners, spots their key momentum levers, and allows smart folks to learn how to get positioned months or even years before the mainstream media finally catches on.
NVAX stock is up over 2,000% on hopes it will deliver a vaccine for the novel coronavirus. However, the real value comes from its influenza vaccine.
With new competition joining the fray in the Covid-19 vaccine race, NVAX stock looks vulnerable. However, the enormous complexity of this arena gives Novavax a fighting chance.
By Thomas Niel
Bottom line: don't bet the ranch, but NVAX stock is a buy as it enters Phase 3 trials.
Novavax is moving ahead with Phase 3 trials in the United Kingdom, and NVAX stock is rallying higher on the news.
By Alex Sirois
NVAX stock is goign to be even more interesting in the next two months. Capacity has risen, and study progress has been made.
The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.
NVAX stock has soared as investors watch its progress on a coronavirus vaccine. But it's not even the front-runner and remains unprofitable.
Novavax has gotten $2 billion in support from the government, and is rushing its COVID-19 vaccine candidate through trials, hoping its adjuvant makes for fast distribution.
The case for NVAX stock is simple: vaccine approval should lead to a significant rally. With progress continuing and the stock cheaper, that case holds.
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader